Roland Magnusson/iStock Editorial via Getty Images
AstraZeneca (AZN) posted stronger-than-expected Q3 results, fueled by continued strength in its oncology portfolio. The U.K. drugmaker reported adjusted EPS of $2.38, well above the $1.13 consensus, while revenue rose 11.9% year-over-year to $15.19B, topping estimates by $420M.
Oncology product sales
If you’ve ever stood in front of the mirror and wondered what your outfit’s missing, Macy’s may have the answer....
Online furniture rental platform Rentomojo has filed for an initial public offering in Mumbai, according to a draft prospectus dated...
President Donald Trump convened what he called the single-largest gathering of American farmers at the White House on Friday, bringing...
The Iran war increasingly looks like the one instance where physical reality has outrun his ability to control the narrative....
Market regulator Securities and Exchange Board of India (Sebi) has approved the initial public offering (IPO) of six companies. The...
Wave Life Sciences (WVE) shares fell nearly 50% to $6.20 after BofA and Wells Fargo cut price targets to $21...
The first and only national digital and print magazine that connects individuals, families, and businesses to Fee-Only financial advisers, accountants, attorneys and college guidance counselors.
